Drugs / CC-38
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07255664 | Nov 2025 → Apr 2027 expected | colorectal cancer, prostate cancer | CuraCell TX AB | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-38 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07255664 ↗ |
| Modality | Cell therapy | “CC-38 drug product is an autologous ATIMP composed of in vitro expanded tumor-infiltrating T-lymphocytes.” NCT07255664 ↗ |